StonvexLoading…
StonvexStonvexStonvexCore line items from TRIP's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $518.11M | $382.40M | $1.89B | $1.48B | $927.00M |
Operating Income | Not available | $-25.20M | $80.00M | $114.00M | $44.00M |
Net Income | Not available | $-32.40M | $40.00M | $78.00M | $25.00M |
EPS (Diluted) | $0.43 | $-0.28 | $0.31 | $0.59 | $0.19 |
Total Assets | Not available | $2.73B | $2.63B | $2.85B | $2.87B |
Total Liabilities | Not available | $2.10B | $1.98B | $2.14B | $2.24B |
Cash & Equivalents | Not available | $1.12B | $1.03B | $1.22B | $1.21B |
Free Cash Flow OCF − CapEx | Not available | $101.30M | $163.00M | $285.00M | $260.00M |
Shares Outstanding | Not available | 116.29M | 114.47M | 116.80M | 116.05M |